Trials / Completed
CompletedNCT01528007
Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention
Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Finnish Institute for Health and Welfare · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this research is to explore the efficacy of the opiate antagonist, naltrexone as combined with CBT-intervention in the treatment of pathological gambling (PG). The study period is 2011-2014 during which one hundred Pathological Gamblers will be recruited to participate to this placebo-controlled double-blind trial.
Detailed description
All participants have to be able to read and understand the patient information sheet and sign the informed consent. All participants are free to stop being in the study whenever they wanted. The patients are not paid or reimbursed for participation. The study periods is 21 weeks during which the participant's have 8 appointments with the researchers. During the meetings research data will be collected and the participant is having Controlled Behavioral Therapy (CBT) consulting from a trained therapist. At the study visits, the subjects are given written instructions for the proper use of naltrexone and advised to take 50 mg naltrexone approximately one hour before gambling or feeling urges to gamble (and to refrain from taking naltrexone at other times). In this study the maximal daily dose is 50mg of naltrexone. The medication is free for the subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Naltrexone pharmacotherapy | Naltrexone 50mg when graving to gamble. |
| DRUG | Placebo | Placebo pill with no active ingredients. |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2012-02-07
- Last updated
- 2013-12-05
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT01528007. Inclusion in this directory is not an endorsement.